Gazyva misses PFS endpoint in first-line DLBCL study

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said Gazyva obinutuzumab plus CHOP chemotherapy missed the primary endpoint of improving progression-free survival vs. Rituxan rituximab plus CHOP in the open-label Phase III GOYA study as a first-line therapy for CD20-positive diffuse large B cell lymphoma.

The study enrolled 1,418 patients and the companies said data will be presented at an upcoming medical meeting. ...